MAPT and Alzheimer disease: In a recent large cohort study, P‐T181‐tau and P‐T231‐tau in plasma NDEVs, quantified using an electrochemiluminescence assay, were able to differentiate participants with future AD from controls, whereas Aβ42 examined with SIMOA assay showed no difference between future AD participants and controls.24